Cadrenal Therapeutics Q2 net loss narrows 9.39% to $3.3 million

Reuters2026/08/13 20:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cadrenal posted a Q2 net loss of USD 3.32 million, narrowing from USD 3.67 million a year earlier.
Operating loss narrowed to USD 3.34 million as total operating expenses fell to USD 3.34 million from USD 3.73 million.
R&D spending dropped to USD 705,151 from USD 1.08 million; G&A edged down to USD 2.63 million from USD 2.66 million.
Cash and cash equivalents were about USD 4.2 million in early August; runway expected through Q1 2027 under the current plan.
Launched a structured partnering process for CAD-1005, frunexian and tecarfarin following Phase 2 CAD-1005 data showing >25% thrombotic-event reduction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131615PRIMZONEFULLFEED9809780) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cadrenal Therapeutics Q2 net loss narrows 9.39% to $3.3 million

You may also like

Crypto prices